ACXP - Acurx Pharmaceuticals, Inc.

1.35
-0.100   -7.407%

Share volume: 64,083
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.14%

PREVIOUS CLOSE
CHG
CHG%
$1.45
-0.10
-0.07%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
37%
Profitability 35%
Dept financing 31%
Liquidity 41%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-8.78%
1 Month
-36.92%
3 Months
-69.53%
6 Months
-67.27%
1 Year
199.93%
2 Year
-53.61%
Key data
Stock price
$1.35
P/E Ratio 
0.00
DAY RANGE
$1.33 - $1.47
EPS 
-$1.67
52 WEEK RANGE
$0.28 - $8.34
52 WEEK CHANGE
$199.93
MARKET CAP 
6.799 M
YIELD 
N/A
SHARES OUTSTANDING 
2.085 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
BETA 
0.71
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$56,836
AVERAGE 30 VOLUME 
$52,922
Company detail
CEO: David P. Luci
Region: US
Website: www.acurxpharma.com
Employees: 3
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria.

Recent news